Mitchell Haut, MD | Cleveland Clinic

Dr. Mitchell Haut

Claim this profile

Cleveland Clinic Mercy Hospital

Expert in Lung Cancer
Studies Non-Small Cell Lung Cancer
35 reported clinical trials
93 drugs studied

Area of expertise

1

Lung Cancer

Global Leader

Mitchell Haut has run 12 trials for Lung Cancer. Some of their research focus areas include:

Stage IV
Stage III
Stage II
2

Non-Small Cell Lung Cancer

Mitchell Haut has run 8 trials for Non-Small Cell Lung Cancer. Some of their research focus areas include:

Stage III
Stage IV
Stage II

Affiliated Hospitals

Image of trial facility.

Cleveland Clinic Mercy Hospital

Image of trial facility.

Mercy Hematology And Oncology Associates Inc

Clinical Trials Mitchell Haut is currently running

Image of trial facility.

Chemotherapy + Immunotherapy

for Esophageal and Gastric Cancer

This phase III trial compares the effect of modified fluorouracil, leucovorin calcium, oxaliplatin, and irinotecan (mFOLFIRINOX) to modified fluorouracil, leucovorin calcium, and oxaliplatin (mFOLFOX) for the treatment of advanced, unresectable, or metastatic HER2 negative esophageal, gastroesophageal junction, and gastric adenocarcinoma. The usual approach for patients is treatment with FOLFOX chemotherapy. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Fluorouracil stops cells from making DNA and it may kill tumor cells. Leucovorin is used with fluorouracil to enhance the effects of the drug. Oxaliplatin works by killing, stopping, or slowing the growth of tumor cells. Some patients also receive an immunotherapy drug, nivolumab, in addition to FOLFOX chemotherapy. Immunotherapy may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Irinotecan blocks certain enzymes needed for cell division and DNA repair, and it may kill tumor cells. Adding irinotecan to the FOLFOX regimen could shrink the cancer and extend the life of patients with advanced gastroesophageal cancers.

Recruiting

2 awards

Phase 3

2 criteria

Image of trial facility.

Standard Therapy + Surgery/Radiation

for Prostate Cancer

This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the body. Addition of prostate removal surgery or radiation therapy to standard systemic therapy for prostate cancer may lower the chance of the cancer growing or spreading.

Recruiting

2 awards

Phase 3

30 criteria

More about Mitchell Haut

Clinical Trial Related

3 years of experience running clinical trials · Led 35 trials as a Principal Investigator · 7 Active Clinical Trials

Treatments Mitchell Haut has experience with

  • Nivolumab
  • Pembrolizumab
  • Atezolizumab
  • Carboplatin
  • Fluorouracil
  • Paclitaxel

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Mitchell Haut specialize in?

Is Mitchell Haut currently recruiting for clinical trials?

Are there any treatments that Mitchell Haut has studied deeply?

What is the best way to schedule an appointment with Mitchell Haut?

What is the office address of Mitchell Haut?

Is there any support for travel costs?